Clinical Trials Logo

Refractory Cancer clinical trials

View clinical trials related to Refractory Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04092179 Terminated - Clinical trials for Acute Myeloid Leukemia

Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

Start date: November 5, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to see how safe and tolerable, and to find the highest or best dose, of an investigational combination of drugs called enasidenib and venetoclax, in patients with relapsed (the cancer has come back) or refractory (the cancer does not respond or have stopped responding to treatment) acute myeloid leukemia (AML, a type of blood cancer). This study will also see how useful the combination of enasidenib and venetoclax is in the treatment of patients with relapsed or refractory AML.

NCT ID: NCT02222363 Terminated - Refractory Cancer Clinical Trials

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

Start date: February 18, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of the investigational drug VLX600 in patients with refractory advanced solid tumors.

NCT ID: NCT01320280 Terminated - Refractory Cancer Clinical Trials

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, BIBW 2992 (Afatinib) has on patients and their advanced prostate cancer which does not respond to hormone or chemotherapy any more. Only patients with tumors which have an increased amounts of a protein called HER2 on their cell surface will be included. BIBW 2992 (Afatinib) is a drug which in advanced clinical testing in lung and breast cancer.